NCT06731673Recruiting
Heat Shock Protein 47 in Thrombosis
Heat Shock Protein 47: A Novel Biomarker of Thrombosis Risk
Source: ClinicalTrials.gov · Last updated 21 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to learn if the novel biomarker Heat shock protein 47 (HSP47) can be used as a prognostic marker for vascular disease in people with acute venous thromboembolism (VTE), myocardial infarction (AMI) or ischaemic stroke compared to healthy volunteers. The main questions it aims to answer are: 1. Are platelet levels of HSP47 higher in patients with acute VTE, AMI or stroke, compared to healthy volunteers. 2. Does platelet levels of HSP47 remain elevated in patients with acute thrombotic events compared to healthy volunteers at 3 and 12-months of follow-up. 3. Are platelet levels of HSP47 postively associated with platelet function and negatively associated with fibrinolytic capacity in patients with an acute thrombotic event. Participants with VTE, AMI or stroke will be giving a blood sample at diagnosis and again after 3 and 12 months of follow-up. Healthy volunteers will be giving a blood sample once.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 340 (estimated)
- First submitted
- 9 Dec 2024
- Start date
- 9 Dec 2024
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- University of Aarhus
- Diseases
- Stroke, Atrial fibrillation
- NCT number
- NCT06731673
What you commit to
- Study type: Observational
- Planned participants: 340
- From 9 Dec 2024 to the primary completion date, 31 Aug 2027
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior VTE, AMI, stroke or other thromboembolic event
Other illness
- Known haematological disorders
- Active haematological malignancy
- Takotsubo cardiomyopathy
- Stroke
- \- Stroke from other causes, e.g. findings pointing towards large vessel disease
- Healthy
- Known acute or chronic disease
Lab values
- Severe renal insufficiency defined as eGFR \<15 or dialysis
- VTE - Pulmonary embolism incidentally detected by CTA conducted for purposes unrelated to pulmonary embolism assessment without concomitant DVT
- AMI
Age
- \<18 years of age
Other
- no informed consent
- Coronary dissection
Who the study is looking for
- 18 years of age or older
- Informed consent
- VTE group:
- Deep vein thrombosis confirmed on ultrasonography OR
- Pulmonary embolism confirmed on computed tomography angiography (CTA)
- AMI group:
- ST-segment elevation on electrocardiogram (ECG) AND
- Culprit lesion(s) on coronary angiography
- Stroke group:
- Stroke confirmed on magnetic resonance imaging AND
- Atrial fibrillation (Detected on ECG, telemtry or Holter monitoring) AND
- Stroke localisation classic for AFib: cortical, cerebellar, brainstem or subcortical \>1.5 cm in diameter
- Healthy group:
- \- Healthy
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Deutsches Herzzentrum de Charité Coordinator of this site? Confirm its status | Berlin | Germany | Recruiting |
| Aarhus University Hospital Coordinator of this site? Confirm its status | Aarhus | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.